Articles

  • 2 months ago | oncologynewscentral.com | Youssef Rddad |Emily Bader

    On April 11, the U.S. Food and Drug Administration (FDA) approved the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with previously untreated unresectable or metastatic hepatocellular carcinoma (HCC). The approval follows a similar regulatory move by the European Commission last week. The FDA based its approval on data from the CheckMate 9DW trial, the results of which were presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.

  • 2 months ago | rnd.de | Patrick Fam |Emily Bader

    Die Schweizer Stadt Basel ist Gastgeber des 69. Eurovision Song Contests. 37 Länder kämpfen um den ESC‑Titel 2025. Wir stellen die Teilnehmenden und ihre Songs vor – hier: Louane aus Frankreich. Weiterlesen nach der AnzeigeWeiterlesen nach der AnzeigeDie StatistikDer SongDer StartplatzIm vergangenen Jahr wurde Frankreich bei den Wettbüros unter den Top Fünf gehandelt – und tatsächlich sicherte sich Slimane mit seiner Liebesballade „Mon Amour“ einen starken vierten Platz.

  • 2 months ago | flipboard.com | Patrick Fam |Emily Bader

    18 hours agoDeutschland: Abor & Tynna - "Baller" | offizielles MusikvideoDeutschland ballert beim ESC! Das Geschwister-Duo Abor und Tynna hat das Finale von "Chefsache ESC 2025" für sich entschieden. [mehr]17 hours agoViele wollten sie beim ESC für Deutschland: Festival bringt „Sieger der Herzen“ nach HessenDas Line-up fürs Butzbach Open Air 2025 steht.

  • 2 months ago | oncologynewscentral.com | Marcia Frellick |Leah Lawrence |Youssef Rddad |Emily Bader

    The standard approach of “7 + 3” chemotherapy in acute myeloid leukemia (AML) treatment has been in place for 50 years. But that may soon change, says Maximilian Stahl, MD, a member of the Adult Leukemia Group at the Dana-Farber Cancer Institute in Boston and a member of the faculty at Harvard University. “My prediction is that in 10 years, you will not see much 7 + 3 anymore. Maybe not even 10 years, maybe five years,” he tells Robert A.

  • 2 months ago | oncologynewscentral.com | Carina Storrs |Emily Bader |Youssef Rddad

    On March 28, the U.S. Food and Drug Administration (FDA) expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have undergone prior androgen receptor pathway inhibition (ARPI) therapy and can postpone taxane-based chemotherapy.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →